<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00035581</url>
  </required_header>
  <id_info>
    <org_study_id>AMP 719</org_study_id>
    <nct_id>NCT00035581</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART</brief_title>
  <official_title>A Multi-Center, Randomized, Controlled Study of the Biological Actions of Ampligen as an Adjunct to HAART in HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemispherx Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hemispherx Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, randomized, controlled study of the safety and efficacy
      including clinical, immunologic, and virologic assessments of adding Ampligen to &quot;HAART&quot; in
      HIV infected patients with CD4 counts &gt;300 and HIV-1 plasma RNA &gt;500 and &lt;30,000 copies/ml
      (PCR).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in HIV-1 Viral Load</measure>
    <time_frame>4, 8, 12, 16, 20 and 24</time_frame>
    <description>Evaluate the effects of adding Ampligen (or no Ampligen) to &quot;HAART&quot; in HIV+ patients for evidence of reductions in HIV-1 viral load in plasma using Roche Amplicor assay.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV Seropositivity</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Ampligen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Ampligen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Ampligen administered for first 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>poly I-poly C12U</intervention_name>
    <description>200-400 mg IV infusions 2x/week for 24 weeks</description>
    <arm_group_label>Ampligen</arm_group_label>
    <other_name>Ampligen</other_name>
    <other_name>Rintatolimod</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Adults at least 18 years of age.

          2. CD4 cell count of &gt;300 cells.

          3. HIV-1 plasma RNA &gt;500 and &lt;30,000 copies/ml.

             A qualifying (&quot;screening&quot;) HIV-1 RNA level &gt;500 and &lt;30,000 copies/ml must be
             documented at least once within 40 days prior to starting Baseline while patient is
             receiving a HAART regimen containing at least two of the following antiretroviral
             drugs:

               -  Abacavir (Ziagen)

               -  Zidovudine (Retrovir) AZT

               -  Zalcitabine (Hivid) ddC

               -  Didanosine (Videx) ddI

               -  Stavudine (Zerit) d4T

               -  Efavirenz (Sustiva)

               -  Indinavir (Crixivan)

               -  Ritonavir (Norvir)

               -  Nelfinavir (Viracept)

               -  Amprenavir (Agenerase)

             The patient must have been taking this HAART regimen for four months or longer at the
             time of the qualifying HIV-1 RNA determination.

          4. History of prior treatment (including the current HAART regimen) with at least one
             protease inhibitor (PI) and at least two nucleoside reverse transcriptase inhibitors
             (NRTI) and/or at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) and
             at least two nucleoside reverse transcriptase inhibitors (NRTI).

          5. Karnofsky performance status of at least 70.

          6. The following laboratory parameters within 14 days prior to treatment:

               -  Hemoglobin &gt; 9.2 g/dL for men and &gt; 8.9 g/dL for women

               -  Neutrophil count &gt; 1000

               -  Platelet count &gt; 75,000

               -  AST/ALT &lt; 4.0 x upper limit of normal (ULN)

               -  Serum creatinine &lt; 1.5 x ULN or a creatinine clearance &gt; 50 mL/min.

          7. For females with child bearing potential: A negative serum pregnancy test within 14
             days prior to randomization. Males and females of child bearing potential agree to use
             an effective means of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Strayer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hemispherx Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Center for Special Immunology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Circle Medical Center</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physicians Group</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julia Torres, MD</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott Ubillos, MD</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W. Chris Woodward, DO</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2002</study_first_submitted>
  <study_first_submitted_qc>May 3, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2002</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment experienced</keyword>
  <keyword>HIV Infections</keyword>
  <keyword>HIV</keyword>
  <keyword>HAART</keyword>
  <keyword>early virologic failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>poly(I).poly(c12,U)</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

